Evidence map›Paper›PMID 29194229›Full record

ArticleOptometry and vision science : official publication of the American Academy of Optometry2017

Patient-Physician Communication on Medication Cost during Glaucoma Visits.

Catherine Slota, Scott A Davis, Susan J Blalock, Delesha M Carpenter, Kelly W Muir, Alan L Robin, Betsy Sleath

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Optometry and vision science : official publication of the American Academy of Optometry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Adherence to Therapy in Glaucoma Treatment-A Review.Journal of personalized medicine · 2022
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Catherine Slota
Scott A DavisDivision of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina.
Susan J BlalockDivision of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina.
Delesha M CarpenterDivision of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina.
Kelly W MuirDepartment of Ophthalmology, Duke University School of Medicine, Durham, North Carolina.
Alan L RobinDepartment of Ophthalmology, University of Maryland, Baltimore, Maryland.
Betsy SleathDivision of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina.
University of North Carolina Health Care · USDuke University · USRTI International · USUniversity of Maryland, Baltimore · US

Funding

Communication About Glaucoma and Patient OutcomesR01EY018400 · NEI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SLEATH, BETSY LYNN · 2009 to 2012
$2.6M
Examining Patient-Provider Communication Regarding Cost in the Glaucoma Patient PR36HS023054 · AHRQ · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GUPTA, CATHERINE · 2014 to 2014
$43k
AHRQ HHS R36 HS023054NEI NIH HHS R01 EY018400
6 · The paper itself

Abstract

significanceThis article is the first to investigate the nature of medication cost discussions between ophthalmologists and glaucoma patients. Only 87 of the 275 office visits analyzed had a discussion of medication cost. Providers should consider discussing medication cost with patients to identify potential cost-related barriers to medication use. PURPOSE: Glaucoma is an incurable chronic eye disease affecting a growing portion of the aging population. Some of the most commonly utilized treatments require lifelong use, requiring high patient adherence to ensure effectiveness. There are numerous barriers to glaucoma treatment adherence in the literature, including cost. The aim of this secondary analysis was to describe the frequency and nature of patient-physician communication regarding medication cost during glaucoma office visits.

methodsThis was a mixed-methods secondary analysis of video-recorded participant office visits (n = 275) from a larger observational study of glaucoma communication. We analyzed medical information, demographic characteristics, and interviewer-administrated questionnaires, as well as verbatim transcripts of interviews.

resultsOnly 87 participants discussed medication cost during their glaucoma office visit. The majority of the subjects who discussed cost had mild disease severity (51%), took one glaucoma medication (63%), and had Medicare (49%) as well as a form of prescription insurance (78%). The majority of glaucoma office visits did not discuss medication cost, and providers often did not ask about cost problems. Of the few conversations related to cost, most focused on providers offering potential solutions (n = 50), medical and prescription service coverage (n = 41), and brand or generic medication choices (n = 41).

conclusionsOur findings are similar to previous studies showing few patients have conversations with providers about the cost of glaucoma medications. Providers should consider bringing up medication cost during glaucoma office visits to prompt a discussion of potential cost-related barriers to medication use.

Indexed as

CommunicationDrug CostsPhysician-Patient RelationsAdultAgedAged, 80 and overAntihypertensive AgentsFemaleGlaucomaHumansMaleMiddle AgedOffice VisitsOphthalmologistsPatient CompliancePatient ParticipationAntihypertensive Agents

Identifiers

PMID29194229
PMCPMC5726412
OpenAlexW2771770655

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.